arrow
Ö

Öztürk Ateş

abdurrahman yurtaslan oncology training and research hospital
H指数:11
被引数:487

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mucosal, Ocular, and Pulmonary Adverse Events Reported with Datopotamab Deruxtecan: An Indication-Restricted Disproportionality Analysis of the FDA Adverse Event Reporting System

达波替尼德鲁克坦报告的黏膜、眼部和肺部不良事件:FDA不良事件报告系统的限定指征不平衡性分析

2026-10-230
OA
Upfront Versus Deferred CDK4/6 Inhibitor Use in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study

激素受体阳性、HER2阴性转移性乳腺癌中即刻与延迟使用CDK4/6抑制剂:一项真实世界研究

2026-08-290
OA
Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

晚期胸腺癌二线治疗的实际疗效:一项多中心土耳其肿瘤学组(TOG)研究

2026-08-270
OA
Guideline adherence in the management of aromatase inhibitor-induced bone loss in women with breast cancer

乳腺癌患者芳香化酶抑制剂诱导的骨丢失管理中的指南依从性

2026-07-280
OAAI
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

CDK4/6抑制剂在胚系BRCA1/2突变、激素受体阳性、HER2阴性转移性乳腺癌中的真实世界疗效:土耳其肿瘤学组(TOG)研究

2026-06-170
OA
The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study

因毒性作用将ribociclib换用palbociclib对激素受体阳性、HER2阴性转移性乳腺癌的影响:一项真实世界、多中心、回顾性研究

2026-03-260
OAAI
Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group

转移性髓样甲状腺癌中的酪氨酸激酶抑制剂治疗:土耳其肿瘤学组的真实世界数据

2026-03-190
OA
Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

曲妥珠单抗德鲁替康在HER2+转移性乳腺癌患者中的真实世界疗效:土耳其肿瘤学组多中心研究

2026-03-130
PRE
Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis

卵巢癌一线PARP抑制剂治疗的结局:一项多中心回顾性分析

2026-02-220
OAAI
Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors-A Turkish Oncology Group Study
CANCERS
IF4.4
2025-12-290
OA
Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study

与健康相关的生活质量和免疫检查点抑制剂治疗长期存活者的心理社会结局:一项全国性多中心研究

2025-12-100
OA
Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study

抗VEGF和抗EGFRs在微卫星不稳定(MSI-H)转移性结直肠癌中的疗效:土耳其肿瘤学组(TOG)队列研究

2025-11-180
OAAI
Induction chemotherapy followed by definitive chemoradiation in patients with inoperable esophageal squamous cell carcinoma: a multicenter retrospective study

不可手术食管鳞状细胞癌患者中诱导化疗后行根治性放化疗:一项多中心回顾性研究

2025-11-180
OAAI